Deanna L. Kirkpatrick

Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Humanigen Inc. of $72 million of common stock. Humanigen Inc. is a clinical…

Davis Polk advised the representatives of the several underwriters, in connection with the initial public offering of 103,500,000 units of Foley Trasimene Acquisition Corp., including…

Davis Polk advised the underwriters in connection with the offering of $1.75 billion aggregate principal amount of 1.050% bonds due May 21, 2027 issued by the Province of Ontario. The Davis…

Davis Polk advised the underwriters in connection with the offering of $1.15 billion aggregate principal amount of notes issued by Lockheed Martin Corporation. The notes were offered in two…

Davis Polk advised the underwriters in connection with the offering of $2.25 billion aggregate principal amount of 1.000% bonds due May 20, 2025, issued by the Province of Alberta. The…

Davis Polk advised ADC Therapeutics SA on its SEC-registered initial public offering of 14,082,475 common shares, which included the exercise in full by the underwriters of their option to…

Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of common stock of Ayala Pharmaceuticals, Inc. Ayala is traded on the…

Davis Polk advised the underwriter in connection with the initial public offering of 30,000,000 units of Sustainable Opportunities Acquisition Corp. for aggregate proceeds of $300…

Davis Polk advised ADC Therapeutics SA in connection with its entry into a facility agreement with Deerfield Partners, L.P., pursuant to which Deerfield agreed to extend senior secured…

Davis Polk advised the representatives of the several underwriters, in connection with the initial public offering of 36,000,000 units of CC Neuberger Principal Holdings I, including 5,400…